PreHevbrio for adult hepatitis B vaccination: EtR and GRADE

Introduction

Kevin Ault, MD
ACIP Hepatitis WG Chair

Hepatitis Vaccines Work Group, Advisory Committee on Immunization Practices
February 16, 2022
Overview: ACIP Hepatitis Work Group

1. Universal adult hepatitis B (HepB) vaccination recommendation – approved 2021

2. FDA Approval of PreHevbrio, a three-antigen HepB vaccine – approved 2021

3. ACIP presentation by manufacturer (VBI) on safety and immunogenicity of PreHevbrio – presented Jan 12, 2022

4. PREHEVBRIO for adult HepB vaccination: EtR and GRADE – Today

5. Subsequent WG term of reference will be to explore preferential use of HepB vaccines among specific risk groups

*https://www.fda.gov/vaccines-blood-biologics/prehevbrio
PreHevbrio for adult HepB vaccination

- **EtR and GRADE: Informational presentation**
  - ACIP Vote is *not* needed, as PreHevbrio will be another non-inferior vaccine option to be used within the existing HepB recommendations

- PreHevbrio will be incorporated into the 2023 immunization schedule as appropriate
ACIP Hepatitis Work Group

ACIP Voting Members
Kevin Ault (Chair)
Sybil Cineas

Liaison Representatives
Elizabeth Barnett (AAP)
Marci Drees (SHEA)
Sharon McMullen (ACHA)
Brenna Hughes (ACOG)
Susan Lett (CSTE)
Pamela Rockwell (AAFP)
Matthew Zahn (NACCHO)

Ex Officio Members
Marian Major (FDA)
Darcie Everett (FDA)
Rajen Koshy (NIAID/NIH)
Chinedu Okeke (HHS)
Jessica Deerin (HHS)

Consultants
Sharon Frey (SLU)
Robert Frenck (CCHMC)
Prabhu Gounder (LA-DPH)
Kathleen Harriman (CDPH)
Brian McMahon (ANTHC)
Kelly Moore (IAC)
David Nace (AMDA)
Jennifer Rosen (NYC-DOH)
Ann Thomas (OR-DHS/OHA)
Jennifer Zipprich (MDPH)

CDC Subject Matter Experts
Erin Conners
Mona Doshani
Brian Edlin
Ruth Gallego
Megan Hofmeister
Neil Murthy
Lakshmi Panagiotakopoulos
Noele Nelson
Priti Patel
Tom Shimabukuro
Phil Spradling
Mark Weng
Carolyn Wester

Acknowledgements
Doug Campos-Outcalt
Rebecca Morgan
Nida Ali, for conducting the PreHevbrio systematic review and creating the GRADE evidence profiles